Galapagos NV to Host Annual R&D Update on 27 March
Published: Mar 21, 2013
MECHELEN, BELGIUM--(Marketwire - March 20, 2013) -
Live presentation at 8 AM ET in New York City
Webcast at 1 PM CET/12 PM GMT, www.glpg.com, 2290 1608
Mechelen, Belgium; 20 March 2013 - Galapagos NV (Euronext: GLPG) will host its annual R&D update in New York City on Wednesday, 27 March.
Formal proceedings will begin at 8:00 am Eastern Time/1:00 pm Central European Time and end at approximately 10:00 am ET/3:00 pm CET. The event will include presentations from Onno van de Stolpe, CEO, and Dr Piet Wigerinck, CSO, who will discuss the progress in the portfolio of novel mode-of-action medicines, and include the plans for the upcoming Phase 2b trial of its selective JAK1 inhibitor GLPG0634.
The presentation will be webcast live and archived on Galapagos' website for one year. To access the live webcast, go to www.glpg.com or click here, call number 2290-1608. To attend this meeting in person, please contact Elizabeth Goodwin at email@example.com.
Galapagos (Euronext: GLPG; OTC: GLPYY) is specialized in novel modes-of- action, with a large pipeline of four clinical, six pre-clinical, and 30 discovery small-molecule and antibody programs in cystic fibrosis, inflammation, antibiotics, metabolic disease, and other indications. GLPG0634 is an orally-available, selective inhibitor of JAK1 for the treatment of rheumatoid arthritis and potentially other inflammatory diseases, about to enter Phase 2b studies. AbbVie and Galapagos signed a worldwide license agreement whereby AbbVie will be responsible for further development and commercialization after Phase 2b. Galapagos has another selective JAK1 inhibitor in Phase 2 in lupus and psoriasis, GSK2586184 (formerly GLPG0778, in-licensed by GlaxoSmithKline in 2012). GLPG0187 is a novel integrin receptor antagonist currently in a Phase 1b patient study in metastasis. GLPG0974 is the first inhibitor of GPR43 to be evaluated clinically for the treatment of IBD; this program will start a Proof of Concept Phase 2 study in Q2 2013. The Galapagos Group, including fee-for-service companies BioFocus, Argenta and Fidelta, has over 800 employees and operates facilities in five countries, with global headquarters in Mechelen, Belgium. Further information at: www.glpg.com
Galapagos forward-looking statements
This release may contain forward-looking statements, including, without limitation, statements containing the words "believes," "anticipates," "expects," "intends," "plans," "seeks," "estimates," "may," "will," "could," "stands to," and "continues," as well as similar expressions. Such forward- looking statements may involve known and unknown risks, uncertainties and other factors which might cause the actual results, financial condition, performance or achievements of Galapagos, or industry results, to be materially different from any historic or future results, financial conditions, performance or achievements expressed or implied by such forward-looking statements. Given these uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements. These forward-looking statements speak only as of the date of publication of this document. Galapagos expressly disclaims any obligation to update any such forward-looking statements in this document to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based, unless required by law or regulation.
Galapagos to host annual R&D update on 27 March: http://hugin.info/133350/R/1686702/553042.pdf
This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Galapagos NV via Thomson Reuters ONE [HUG#1686702]
Director Investor Relations
Tel: 6 2291 6240